HALO
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Article Summary
BUY- Halozyme Therapeutics (NASDAQ: HLZN) signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in patients with mutCALR-expressing myeloproliferative neoplasms.
- The partnership will use Halozyme's Enhanze drug delivery technology to potentially improve convenience of administering the antibody therapy, with the companies aiming to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.
- Under the agreement, Halozyme is eligible for an upfront payment from InCyte and additional milestone-based payments and royalties on net sales of commercial medicines developed using the Enhnze technology.
- The agreement builds on Halozyme's established track record of successful collaborations with leading biopharmaceutical companies including Roche, Pfizer, AbbVie, and Bristol-Myers Squibb, with more than one million patients having received products using the technology.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 39.1% | 25% | 85.0 ptsExcellent (39.1%) - Strong growth |
| EPS Growth Next 5Y ? | 39.0% | 25% | 90.0 ptsExcellent (39.0%) - Strong outlook |
| Target Price Upside ? | 7.5% | 20% | 35.0 ptsBelow Screener (7.5%) - Target: $83.90 vs Current: $78.08 |
| Gross Margin % ? | 76.9% | 15% | 100.0 ptsExceptional (76.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -5.1% | 15% | 20.0 ptsBarely a Dip (-5.1%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About HALO
- Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
- The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
- The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
- It has collaborations and licensing agreements with F.
- Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc.
- The company was founded in 1998 and is headquartered in San Diego, California.